B2M and colorectal carcinoma: Although acquired mutations in Janus Kinase (JAK) 1, JAK2, and beta 2-microglobulin (B2M) are markers of resistance to PD-1 blockade in melanoma [142], their role in patients with CRC is not yet well defined.